Enanta Pharmaceuticals | ENTA - Loan Capital


Enanta Pharmaceuticals reported $0 in Loan Capital for its fiscal quarter ending in December of 2024.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Amgen USD 50B 2.43B Dec/2025
Arrowhead Research USD 538.1M 323.22M Dec/2025
AstraZeneca USD 26.14B 19.58B Dec/2025
BioCryst Pharmaceuticals USD 428.67M 234.31M Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Enanta Pharmaceuticals USD 0 0 Dec/2024
Gilead Sciences USD 22.14B 5M Sep/2025
GlaxoSmithKline GBP 14.71B 186M Dec/2025
Halozyme Therapeutics USD 2.14B 1.34B Dec/2025
Heron Therapeutics USD 140.64M 975K Dec/2025
Immunic USD 0 0 Jun/2024
Incyte USD 30.2M 5.17M Dec/2025
Insmed USD 540.96M 1.24M Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
J&J USD 39.44B 30M Dec/2025
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
Ligand Pharmaceuticals USD 445.49M 445.44M Sep/2025
Merck USD 39.97B 6B Sep/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 29.59B 5.35B Dec/2025
Novavax USD 246.3M 200K Dec/2025
Pfizer USD 57.41B 93M Sep/2025
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025